Original from: mddionline

Author: Omar Ford

Hologic has launched its Novodiag system in Europe. The Waltham, MA-based company inherited the automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance when it acquired Mobidiag Oy for $795 million.

The Novodiag system combines real-time PCR and microarray capabilities. This enables multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing. Its CE-IVD test menu includes highly multiplexed on-demand assays detecting gastrointestinal infections and antibiotic resistance, as well as a targeted assay for the detection of SARS-CoV-2.

“Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With the Hologic launch of the Novodiag system, we are delivering against this goal,” said Jan Verstreken, Group President, International at Hologic. “The addition of the Novodiag system to our diagnostic molecular scalable solutions portfolio will offer more customers in Europe a wider choice of solutions that meet their needs, from single patient rapid testing to population-level screening.”

Hologic, fueled from its COVID-19 testing sales, began a huge acquisition spree kicking off 2021 with the acquisition of Somatex for $64 million. The deal would help the firm expand its breast health solutions.

Within the same week of the Somatex deal, Hologic announced it would acquire Biotheranostics, a private company that provides molecular diagnostic tests for breast and metastatic cancers, for $230 million. The company then acquired Diagenode for $159 million.

Source: Hologic Launches Molecular Diagnostic Solution in Europe